Cabometyx (cabozantinib)
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Cabometyx (cabozantinib), covering 2025-06-11 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study [Phase 3]